ED
KRTX

Exane Derivatives’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Exane Derivatives’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$93.6K Hold
740
– – 0.05% 270
2022
Q1 		$93.8K Sell
740
-63
-8% -$7.09K 0.03% 482
2021
Q4 		$105K Buy
+803
New +$104K 0.03% 436

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Exane Derivatives's KRTX Position: Q2 2022 in Review

Exane Derivatives held its Karuna Therapeutics, Inc. Common Stock (KRTX) position steady in Q2 2022 at 740 shares worth $93.6K. The position accounts for 0.05% of the portfolio, ranked #270.

Exane Derivatives first reported a position in KRTX in Q4 2021 and has held it in 3 quarters since. The position peaked at $105K in Q4 2021. 195 funds tracked by Wall St. Rank hold KRTX as of Q2 2022.

  • Exane Derivatives held 740 shares of Karuna Therapeutics, Inc. Common Stock worth $93.6K as of Q2 2022.
  • Exane Derivatives left its Karuna Therapeutics, Inc. Common Stock share count unchanged in Q2 2022.
  • Karuna Therapeutics, Inc. Common Stock made up 0.05% of Exane Derivatives's portfolio in Q2 2022, its #270 holding.
  • Exane Derivatives first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2021 and has held it in 3 quarters since.
  • Exane Derivatives's Karuna Therapeutics, Inc. Common Stock position peaked at $105K in Q4 2021.
  • 195 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.